CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


FAVIR 200 MG FTWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug114 AVIGAN 200 mg FT Wiki 1.00
drug2748 Streptokinase Wiki 1.00
drug3009 Unfractionated heparin Wiki 0.71

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Favir 200 Mg Ft In Comparison With Avigan 200 Mg Ft In Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

NCT04444986 Bioequivalence Drug: FAVIR 200 MG FT Drug: AVIGAN 200 mg FT

Primary Outcomes

Description: AUC0-tlast of favipiravir obtained by plasma concentration

Measure: AUC0-tlast of favipiravir

Time: 0 to 24 hours post-dose

Description: Cmax of favipiravir obtained by plasma concentration

Measure: Cmax of favipiravir

Time: 0 to 24 hours post-dose

Secondary Outcomes

Description: AUC0-inf of favipiravir obtained by plasma concentration

Measure: AUC0-inf of favipiravir

Time: 0 to 24 hours post-dose

Description: tmax of favipiravir obtained by plasma concentration

Measure: tmax of favipiravir

Time: 0 to 24 hours post-dose


No related HPO nodes (Using clinical trials)